Earnings surprises can have a huge impact on a company's stock price. Now the stock price is moving -17.13% off from the highest level of twelve months and 8.46% above from twelve months low.
In order to reach an opinion and communicate the value and volatility of a covered security, analysts research public financial statements, listen in on conference calls and talk to managers and the customers of a company, typically in an attempt to capture the findings for a research report. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/09/wells-fargo-company-analysts-give-flexion-therapeutics-inc-flxn-a-39-00-price-target.html.
Equity analyst Northland Securities added FLXN to its research portfolio by announcing an initial rating of "Outperform".
02/07/2017 - Flexion Therapeutics Inc had its "outperform" rating reiterated by analysts at BMO Capital Markets. Finally, Zacks Investment Research upgraded Flexion Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, July 5th. The stock closing price is now trading upward to its 50 day moving average with change of 25.35%, escalated to its 20 day moving average with figure of 20.00% and above its 200 day moving average with value 38.57%. They may also be used to assist the trader figure out proper support and resistance levels for the stock.
Flexion Therapeutics, Inc. (FLXN) now has a Return on Assets (ROA) value of -38.2 Percent. The company's market cap is $952.55 Million, and the average volume is 674.64 Million. The stock's 50 day moving average price is $22.71 and its 200-day moving average price is $20.56. (NASDAQ:FLXN) traded up 10.36% in the last session while performance was up 29.93% in the last five days.
While considering EPS estimates of the company, it has next quarter growth estimates of 0.57 whereas during current year it has 2.07 estimations over growth, comparing to the estimations of 2.25 during next year.
ILLEGAL ACTIVITY WARNING: "Janney Montgomery Scott Boosts Flexion Therapeutics, Inc. (FLXN)" was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of US & global trademark and copyright law. The stock price hovered in an intraday range of $1.72- $1.95. However the six-month change in the insider ownership was recorded 5.67%, as well as three-month change in the institutional ownership was recorded -0.03%. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website.
Analysts' ultimate objective when projecting revenue is to determine the appropriate value for a stock. The institutional investors might have bought a large chunk of stocks of the company. Company insiders own 15.98% of the company's stock. Fiduciary Trust Co. purchased a new position in shares of Flexion Therapeutics during the second quarter valued at about $101,000. Guggenheim Capital LLC acquired a new stake in Flexion Therapeutics during the fourth quarter worth $1,326,000. Short interest grew from 6,308,723 to 6,676,026 over that period. It is positive, as 17 investors sold Flexion Therapeutics Inc shares while 17 reduced holdings. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company's stock valued at $441,000 after purchasing an additional 811 shares during the last quarter. Janney Montgomery Scott LLC now owns 13,575 shares of the specialty pharmaceutical company's stock worth $365,000 after buying an additional 3,200 shares during the last quarter.
Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA, a type of degenerative arthritis.
Indication: ZILRETTA™ (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.